- Home
- SPCE vs ZNTL Comparison
SPCE vs ZNTL Comparison
Compare SPCE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPCE | ZNTL |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 156.7M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPCE | ZNTL |
|---|---|---|
| Price | $2.97 | $2.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $3.26 | ★ $5.80 |
| AVG Volume (30 Days) | ★ 4.8M | 530.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | 18.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | $2,766.13 | N/A |
| Revenue Next Year | $699.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.13 | $1.01 |
| 52 Week High | $5.59 | $3.95 |
Technical Indicators
Market Signals| Indicator | SPCE | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 64.53 | 52.84 |
| Support Level | $2.91 | $1.31 |
| Resistance Level | $3.42 | $2.69 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 81.86 | 79.71 |
Price Performance
Historical ComparisonAbout SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.